AMGNAmgenSigning up patients
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Secondary Hyperparathyroidism · Chronic Kidney Disease
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 56 (planned)
- Started
- Apr 29, 2019
- Main results expected
- Jan 31, 2029
- Fully finished
- Jan 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Achieving a ≥ 30% Reduction from Baseline in Mean iPTH During the Efficacy Assessment Period (EAP)
Measured over: Baseline and Weeks 20-27
Percentage Change from Baseline in Mean iPTH During the EAP
Measured over: Baseline and Weeks 20-27
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03633708 · record last updated 2026-02-27 · checked 2026-11-09 15:42 UTC